)

Genscript Biotech (1548) investor relations material
Genscript Biotech H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Revenue from continuing operations rose 81.9% year-over-year to $518.8M in H1 2025, driven by strong license revenue and growth across all core business segments.
Adjusted net profit from continuing operations reached $178.0M, up 509.6% year-over-year; reported net loss narrowed to $24.5M, mainly due to deconsolidation and a $193.7M share of loss from Legend Group.
Cash and bank balances, including wealth management products, totaled $966.6M as of June 30, 2025, supporting global expansion, R&D, and automation initiatives.
Significant operational progress included global brand relaunch, platform enhancements, and expansion of manufacturing capacity.
ESG achievements include EcoVadis Silver, MSCI AA rating, FTSE4Good inclusion, and ISO 27001 certification for all global entities.
Financial highlights
Revenue: $518.8M (+81.9% YoY); Gross profit: $320.6M (+140.1% YoY); Adjusted net profit: $178.0M (+509.6% YoY); Net loss: $24.5M (vs. $215.6M loss prior year).
Life Science Group revenue up 11.3% to $247.6M; ProBio up 511.1% to $246.9M; Bestime/Industrial synthetic biology up 8.4% to $28.3M.
Life Science Group adjusted gross profit $126.3M (+5.3% YoY), margin 51%; ProBio adjusted gross profit $181.6M, margin 73.6%; Bestime/Industrial synthetic biology adjusted gross profit $11.4M, margin 40.4%.
ProBio adjusted EBITDA $164.2M; cash position $371.1M.
Group cash position at $970M, supporting expansion and R&D.
Outlook and guidance
FY 2025 revenue growth target revised to 13–15% for core business; Life Science expects flat adjusted gross profit and 18% operating margin.
ProBio expects 15–20% fee-for-service revenue growth, new milestone payment in H2, and continued LaNova out-licensing payments.
Bestime/Industrial synthetic biology targets 20–25% revenue growth, ~45% adjusted gross profit margin, and faster H2 growth due to seasonality.
Group to expand manufacturing in the US, Singapore, and China, launch new GMP Plasmid and AAV capabilities, and accelerate portfolio transformation.
Next Genscript Biotech earnings date

Next Genscript Biotech earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage